Alzheimer’s patients in the European Union will have to keep waiting for new treatments after regulators blocked a drug that’s already been approved in the United States and the United Kingdom.
The drug donanemab, sold by Eli Lilly as Kisunla, is a monoclonal antibody that slowed the progression of Alzheimer’s for people with early stages of the disease in a key clinical trial. It’s taken via a once-monthly infusion.
